- Home
- MIND vs BCAB Comparison
MIND vs BCAB Comparison
Compare MIND & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIND | BCAB |
|---|---|---|
| Founded | 1987 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.4M | 71.6M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MIND | BCAB |
|---|---|---|
| Price | $9.01 | $0.54 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 265.0K | ★ 1.6M |
| Earning Date | 12-09-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $46,195,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.08 | N/A |
| P/E Ratio | $23.50 | ★ N/A |
| Revenue Growth | ★ 2.21 | N/A |
| 52 Week Low | $4.45 | $0.24 |
| 52 Week High | $14.50 | $1.43 |
Technical Indicators
Market Signals| Indicator | MIND | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 49.16 | 35.75 |
| Support Level | $8.65 | $0.63 |
| Resistance Level | $9.25 | $0.82 |
| Average True Range (ATR) | 0.57 | 0.11 |
| MACD | 0.13 | -0.02 |
| Stochastic Oscillator | 80.46 | 1.07 |
Price Performance
Historical ComparisonAbout MIND MIND Technology Inc. (DE)
MIND Technology Inc provides technology and solutions for exploration, survey, and defense applications in oceanographic, hydrographic, defense, seismic, and security industries. The company operates in segments namely, Seamap Marine Products and Klein Marine Products helps manufacture and sell specialized, high-performance sonar and seismic equipment. The company generates more revenue from Seamap Marine Products. The company's geographical segments include the United States; China, Norway; Turkey; Singapore; and Canada & Other.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.